Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Treatment and Pharmacology, Lung Cancer Treatments and Mutations, HER2/EGFR in Cancer Research, and Colorectal Cancer Treatments and Studies.
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma.
ctDNA Analysis in <i>ERBB2</i> -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
ctDNA Analysis in ERBB2-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial.
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.
Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Table S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table 1 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Table S2 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure S1 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Data from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Supplementary Table S2 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Data from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Figure 3 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Table S3 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Table S4 from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Figure 2 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Figure 1 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Data from ctDNA Analysis in <i>ERBB2</i>-Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway Trial
Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma
Supplementary Table S1 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Supplementary Figure S1 from Phase I Study of the Mutant <i>IDH1</i> Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma
Suppl Figures 1 from The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial
Table 4 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma